Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of $0.06, $0.64 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $593.16 million versus the consensus estimate of $580.61 million.

GUIDANCE:

Alnylam Pharma sees FY2025 revenue of $2.05-2.25 billion, versus the consensus of $2.68 billion.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.